He said it in the press release when they pre-announced the quarterly revenue numbers. He stated they will be issuing a shareholder letter later this month (January). Here’s the quote...
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "Our record financial performance in 2020 reflects the underlying strength of our core businesses in critical care and cardiac surgery, aided by broad-based demand for CytoSorb as a powerful therapy to treat cytokine storm and hyperinflammation in mechanically ventilated COVID-19 patients. By leveraging our existing businesses, with new opportunities such as liver disease and the removal of blood thinners in cardiothoracic surgery, we believe 2021 will be another year of strong growth. We plan to provide more detail on the year ahead in a stockholder's letter later this month."